Sickle cell trait (SCT) is a genetic condition characterized by a heterozygous A-T substitution (Glu to Val) in 1 copy of the β-globin (HBB) gene on chromosome 11. Although often asymptomatic, individuals with SCT can experience complications under stress, such as hypoxia, dehydration, and extreme exertion, leading to vaso-occlusion, organ damage, and impaired immune defenses. Understanding the impact of SCT on the immune system may aid in preventing clinical complications. We genotyped 720 newborns from The Gambia, West Africa, an area in which people are prone to have sickle cell disorders, using RNA-sequencing reads mapped to the HBB gene to identify those with SCT and investigate immune development using single-omics and multiomics approaches. We identified 118 newborns (~17%) with SCT and 4 (0.6%) with sickle cell disease (SCD). Newborns with SCT demonstrated distinct molecular signatures across day of life (DOL) 0, 1, 3, and 7, compared with those without, including reduction of DOL 3 plasma proteins (eg, cysteine-rich secretory protein-3, inter-α-trypsin inhibitor 1, tetranectin, and cadherin-5). Additionally, we observed enrichment of pathways previously associated with SCD, such as the Jison sickle cell pathway, along with those linked to hematologic (chronic leukemia), hepatic (liver cancer), and renal (aging kidney) functions and disorders. These SCT-based associations were validated in an independent cohort of 45 neonates. Despite the absence of overt early clinical phenotypes, SCT-associated changes manifest in the first week of life at the molecular level. Monitoring and characterizing these associations may enable the identification of future disease risks and the development of preventive strategies. This trial was registered at www.clinicaltrials.gov as #NCT03246230.